We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Handsome are one of the leading brands of back care stocked in over 1000 stores such as boots and CVS Pharmacy. They stock a comprehensive range of award winning products for pain relief and posture management and aim to become the leading consumer brand in back care through their brand BAC< BackPainHelp.
days to go: Expired investment: £514,530
Arcis Biotechnology provide nucleic acid sample preparation solutions. They have made the process of obtaining genetic material from biological samples less time consuming so it can be done in less than 3 minutes.
days to go: Expired investment: £1,146,318
Amchara Health specialises in bringing a better approach to creating a personalised health solution tailored to a person's needs and goals. Its aim is to educate and empower people about better health choices. This residential retreat brand is developing three health & wellness applications: HealthHub360, MyAmchara, and Amchara360. In the first 12 months, the company will aim to achieve more than 100,000 downloads of the Healthhub360 application. With the proceeds, Amchara will be marketing the MyAmchara app and rebrand it. Furthermore, there will be an international development of the application to cater to Canada, Australia, and the USA.
days to go: Expired investment: £167,619
Personalised Co. is a nutrition company on a mission to help as many people as possible reach their health and wellbeing goals by making supplements accessible and affordable. The company asserts that it provides personalised nutritional products to its consumers. Customers are required to take a quiz on the company's portal, based on which, the company's custom-built algorithm creates nutritionist-approved solutions tailored to the specific needs and goals of each customer. Personalised Co. has delivered 270,000 daily vitamin sachets till date. The company has also raised £192,000 from private investors and its first crowdfunding campaign in 2019. It achieved its milestone month in April 2020 earning £48,000 in revenue and delivering over 1,700 personalised vitamins and protein orders. The company will use the investment to level-up its operations, expand its product line and develop its companion-application.

Pitch Rated

54%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £401,417
Stablepharma invents a disruptive solution that can eliminate waste and supply life-saving vaccines without refrigeration. It is a patented invention that allows vaccines to be stored for years and transported without refrigeration whilst adhering with the protocols established by the WHO. Its current project plan comprises the Tetanus vaccine processed by Clinical Trials in Humans. The success of this project will significantly enhance the value of the invention and allow it to set up a pilot scale production in the $36 bn human vaccine market.
days to go: Expired investment: £1,310,090
Rightangled are a CQC registered healthcare provider specialising in genetic testing and is backed by the NHS England. They have designed and filed a patent for their Cardiac genetic test and are now seeking to expand their testing and telemedicine service into new markets and new tests.
days to go: Expired investment: £433,290
Their unique adiposet system dramatically improves the patient experience of breast reconstruction following breast cancer treatment, whilst improving clinical practice and reducing cost to NHS and private hospitals. Adiposet also has applications in many other therapeutic and cosmetic procedures.
days to go: Expired investment: £446,380
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph